SARS-CoV-2 specific immune responses in overweight and obese COVID-19 patients

Front Immunol. 2023 Nov 2:14:1287388. doi: 10.3389/fimmu.2023.1287388. eCollection 2023.

Abstract

Obesity is a known risk factor for severe respiratory tract infections. In this prospective study, we assessed the impact of being obese or overweight on longitudinal SARS-CoV-2 humoral and cellular responses up to 18 months after infection. 274 patients provided blood samples at regular time intervals up to 18 months including obese (BMI ≥30, n=32), overweight (BMI 25-29.9, n=103) and normal body weight (BMI 18.5-24.9, n=134) SARS-CoV-2 patients. We determined SARS-CoV-2 spike-specific IgG, IgA, IgM levels by ELISA and neutralising antibody titres by neutralisation assay. RBD- and spike-specific memory B cells were investigated by ELISpot, spike- and non-spike-specific IFN-γ, IL-2 and IFN-γ/IL-2 secreting T cells by FluoroSpot and T cell receptor (TCR) sequencing was performed. Higher BMI correlated with increased COVID-19 severity. Humoral and cellular responses were stronger in overweight and obese patients than normal weight patients and associated with higher spike-specific IgG binding titres relative to neutralising antibody titres. Linear regression models demonstrated that BMI, age and COVID-19 severity correlated independently with higher SARS-CoV-2 immune responses. We found an increased proportion of unique SARS-CoV-2 specific T cell clonotypes after infection in overweight and obese patients. COVID-19 vaccination boosted humoral and cellular responses irrespective of BMI, although stronger immune boosting was observed in normal weight patients. Overall, our results highlight more severe disease and an over-reactivity of the immune system in overweight and obese patients after SARS-CoV-2 infection, underscoring the importance of recognizing overweight/obese individuals as a risk group for prioritisation for COVID-19 vaccination.

Keywords: COVID-19; TCR; cellular; neutralising; obesity; overweight; spike; vaccination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19 Vaccines
  • COVID-19*
  • Enzyme-Linked Immunospot Assay
  • Humans
  • Immunity
  • Immunoglobulin G
  • Interleukin-2
  • Obesity / complications
  • Overweight*
  • Prospective Studies
  • SARS-CoV-2

Substances

  • COVID-19 Vaccines
  • Interleukin-2
  • Immunoglobulin G
  • Antibodies, Viral
  • Antibodies, Neutralizing

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was funded by the Trond Mohn Stiftelse (TMS) [TMS2020TMT05], Ministry of Health and Care Services, Norway, the University of Bergen, Norway, and Helse Vest, Norway (F-12621). The Influenza Centre is supported by the Norwegian Research Council Globvac [284930]; the European Union [IMI2 101007799 Inno4Vac, H2020 874866 INCENTIVE, H2020 101037867 Vaccelerate]. The Research Unit for Health Surveys (RUHS) received support from TMS.